Market Research Logo

Global Hereditary Angioedema Market: Industry Analysis & Outlook (2017-2021)

Global Hereditary Angioedema Market: Industry Analysis & Outlook (2017-2021)

Hereditary Angioedema (HAE) is a rare hereditary disease caused by a genetic deficiency in a gene known as C1 inhibitor (C1-INH). It is characterized by attacks of edema (swelling). These are unpredictable and can affect various areas of the body including the stomach, hands, feet, arms, legs, genitals, throat, and face. Depending on the severity of the disease, some people can have many attacks each month, while others go months without an attack.

During an HAE attack, swelling can happen in a variety of places. This includes the hands, feet, genitals, gastrointestinal (GI) tract, and throat. Symptoms last about 2 to 5 days and then slowly decrease. Although people are born with a genetic defect, the symptoms start in childhood and worsen during teenage years. Many people do not know they have HAE until they are diagnosed in adulthood.

There are three types of hereditary angioedema, called type I, II, and III, which can be distinguished by their underlying causes and levels of a protein called C1 inhibitor in the blood. The classification of HAE into 3 types is based on what problem the genetic defect causes. Treatment of HAE relies on long–term prophylaxis, short–term prophylaxis, and the treatment of acute attacks. The long–term goal is to minimize the frequency and severity of angioedema episodes.

The global hereditary angioedema market is set to experience favourable growth driven by factors such as increasing diagnosis of hereditary angioedema & rising health care expenditure. Further, the scope of growth for this market will be broadened by increasing uptake of prophylaxis therapy and global economic development. The major trends that can be observed in this market include introduction of novel drugs, increasing awareness for HAE and oral medication for HAE attacks.

The report “Global Hereditary Angioedema Market: Industry Analysis & Outlook (2017-2021)” analyses the development of this market, with focus on the U.S. and European markets. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players Shire Plc., CSL Limited, Pharming Group N.V. & BioCryst Pharmaceuticals Inc. are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global Hereditary Angioedema market along with the study of the regional markets.


1. Overview
1.1 Introduction
1.2 Symptoms
1.3 Types of HAE
1.4 Treatment Options
Table 1: Types of Hereditary Angioedema (HAE)
Table 2: Hereditary Angioedema Treatment Therapies
2. Global Hereditary Angioedema Market
2.1 Global Hereditary Angioedema Market Forecast by Value
Table 3: Global Hereditary Angioedema Market Forecast by Value (2016-2021)
2.2 Global Hereditary Angioedema Market by Drug
Table 4: Global Hereditary Angioedema Market by Drug (2016)
2.3 Global Hereditary Angioedema Drug Revenue
2.3.1 Global Cinryze Revenue Forecast by Value
Table 5: Global Cinryze Revenue Forecast by Value (2016-2021)
2.3.2 Global Haegarda/Berinert Revenue Forecast by Value
Table 6: Global Haegarda/Berinert Revenue Forecast by Value (2016-2021)
3. Regional Market
3.1 The U.S.
3.1.1 The U.S. Total Hereditary Angioedema & Diagnosed Patients
Table 7: The U.S. Total Hereditary Angioedema & Diagnosed Patients (2016-2021)
3.1.2 The U.S. Hereditary Angioedema Patient Population on Prophylaxis
Table 8: The U.S. Hereditary Angioedema Patient Population on Prophylaxis (2016-2021
3.1.3 The U.S. Hereditary Angioedema Market by Drug
Table 9: The U.S. Hereditary Angioedema Market by Drug (2016)
3.1.4 The U.S. Cinryze Revenue Forecast by Value
Table 10: The U.S. Cinryze Revenue Forecast by Value (2016-2021)
3.1.5 The U.S. Haegarda/Berinert Revenue Forecast by Value
Table 11: The U.S. Haegarda/Berinert Revenue Forecast by Value (2016-2021)
3.2 Europe
3.2.1 Europe Total Hereditary Angioedema & Diagnosed Patients
Table 12: Europe Total Hereditary Angioedema & Diagnosed Patients (2016-2021)
3.2.2 Europe Hereditary Angioedema Patient Population on Prophylaxis
Table 13: Europe Hereditary Angioedema Patient Population on Prophylaxis (2016-2021)
3.2.3 Europe Hereditary Angioedema Market by Drug
Table 14: Europe Hereditary Angioedema Market by Drug (2016)
3.2.4 Europe Cinryze Revenue Forecast by Value
Table 15: Europe Cinryze Revenue Forecast by Value (2016-2021)
3.2.5 Europe Haegarda/Berinert Revenue Forecast by Value
Table 16: Europe Haegarda/Berinert Revenue Forecast by Value (2016-2021)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increasing Diagnosis in the U.S. and Europe
Table 17: Diagnosis Rate in the U.S. and Europe (2016-2021)
4.1.2 Accelerating Economic Growth
Table 18: Global GDP Per Capita (2012-2016)
4.1.3 Rising HealthCare Expenditure
Table 19: Global HealthCare Expenditure Per Capita (2012-2016)
4.1.4 Upsurge in Disposable Income
Table 20: Global GNI Per Capita (2012-2016)
4.1.5 Increase in the Uptake of Prophylaxis Therapy
4.2 Key Trends & Developments
4.2.1 Upcoming Novel Drugs
Table 21: Pipeline Drugs in Development for HAE (2016)
4.2.2 Increasing Awareness about HAE
4.2.3 Oral Medication for HAE Attacks
4.3 Challenges
4.3.1 Stringent Regulations
4.3.2 High Cost of HAE Drugs
4.3.3 Misdiagnosis of Hereditary Angioedema Disorder
4.3.4 Limitation of Clinical Trials
4.3.5 Side Effects of HAE Drugs
5. Competition
5.1 Global Market
5.1.1 Revenue and Market Cap Comparison
Table 22: Global Hereditary Angioedema Key Players - Revenue & Market Cap Comparison (2016)
5.1.2 Global Hereditary Angioedema Market - Drug Comparison
Table 23: Global Hereditary Angioedema Market - Drug Comparison (2016)
6. Company Profiles
6.1 Shire Plc.
6.1.1 Business Overview
Table 24: Shire Plc. Sales by Therapeutic Areas (2016)
6.1.2 Financial Overview
Table 25: Shire Plc. Revenue and Net Income (2012-2016)
6.1.3 Business Strategies
Table 26: Shire Plc. Research & Development Expenses (2014-2016)
6.1.3 Business Strategies
Table 27: Shire Plc. Collaborations and Acquisitions (2016/2017)
6.2 CSL Limited
6.2.1 Business Overview
Table 28: CSL Limited Revenue by Segments (2016)
6.2.2 Financial Overview
Table 29: CSL Limited Revenue and Net Profit (2012-2016)
6.2.3 Business Strategies
Table 30: CSL Limited Research & Development Expenses (2014-2016)
6.3 Pharming Group N.V
6.3.1 Business Overview
Table 31: Pharming Group N.V. Revenue by Geographic Region (2016
6.3.2 Financial Overview
Table 32: Pharming Group N.V. Revenue and Net Loss (2012-2016)
6.3.3 Business Strategies
Table 33: Pharming Group N.V. Research & Development Expenses (2014-2016
6.4 BioCryst Pharmaceuticals Inc.
6.4.1 Business Overview
Table 34: BioCryst Drug Development Programs (2016)
6.4.2 Financial Overview
Table 35: BioCryst Pharmaceuticals Inc. Revenue and Net Loss (2012-2016)
6.4.3 Business Strategies
Table 36: BioCryst Pharmaceuticals Inc. Research and Development Expenses (2014-2016)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report